• 1 mGlu4 Modulators Kevin Liu2 Recent Advances towards Pain Therapeutics Philippe Nantermet3 Circadian Rythym Paul Galatsis4 Recent Progress in the Discovery of Kv7.x Modulators’ Ismet Dorange5 Bile Acid Receptor Modulators for Treatment of Metabolic Diseases Yanping Xu6 Mineralocorticoid Receptor Antagonists Katerina Leftheris7 SGLT2 Inhibitors for the Treatment of Diabetes Jiwen Liu, TaeWeon Lee8 CRTh2 Antagonists Laurence E. Burgess9 Developments and Advances in Gastrointestinal Prokinetic Agents James W. Dale10 Targeting Th17 and Treg Signaling Pathways in Autoimmunity Shomir Ghosh11 Advances in the Discovery of C5a Receptor Antagonists Jay P. Powers12 Inhibition of Translation Initiation as a Novel Paradigm for Cancer13 The Development of Inhibitor of Apoptosis Protein Antagonists for the Treatment of Resistant Cancers. Stephen Condon14 Case History on the Discovery of Halaven® Melvin Lu15 Emerging New Therapeutics against Key Gram-negative Pathogens Daniel Obrecht16 Hepatitis C Virus Inhibitors – Beyond NS3 Protease and NS5B17 The Emergence of Small Molecule Modulators of the Capsid Assembly Pathway as Potential Antiviral Therapeutics Clarence R. Hurt 18 Mechanism of Action (MoA) in Drug Discovery David Swinney19 Aryl Hydrocarbon Receptor (AhR) Activation: An Emerging20 Prolyl Isomerases Pat Flaherty21 Potential Therapeutic Applications of miRNA Graham Brock22 Induced Pluripotent Stem Cells (iPSC) as Drug Discovery Tools and Human Disease Models Charles R. Johnson23 Progress in Drug Repositioning: Old Drugs, New Opportunities Michael A. Walters 24 Deuterium in Drug Discovery and Development Scott L. Harbeson25 Phospholipidosis Peter Bernstein26 To Market, To Market 2010 Joanne Bronson

This series is one of the very few annual publications which justify the title of an absolute must for the pharmacologist, chemist, or physician who is interested in the chemistry of drug development." --ENZYMOLOGIA